Left ventricular hypertrophy (LVH) is very common in haemodialysis patients. We measured left ventricular mass in three groups of haemodialysis patients: group A (n = 40) were normotensive and receiving a strict salt-restricted diet; group B (n = 23) were normotensive and receiving antihypertensive drugs; and group C (n = 43) were hypertensive despite anti-hypertensive drug treatment. The interdialytic weight gain in group B and group C was significantly higher than in group A; the mean left atrial index and left ventricular end-systolic and end-diastolic diameter indices were all higher in group B than in group A. The interventricular septum and posterior wall were significantly thicker in group B and group C than group A, resulting in a higher left ventricular mass index. Left ventricular systolic and diastolic function parameters were slightly better in group A than in the other groups. These results show that strict fluid volume control decreases blood pressure, reduces dilated cardiac compartments and corrects LVH more effectively than lowering blood pressure without correcting the volume overload.
Introduction
Cardiovascular disease is the leading cause of death in patients with end-stage renal disease (ESRD), being responsible for 43 -52% of the overall mortality. 1, 2 Cardiac death is up to 10 -20 times more frequent in uraemic patients than in the general population. 3 Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor related to overall mortality in such patients. 4 The prevalence of LVH in dialysis patients has been estimated as being between 70% and 80%. 5 While it has been reported that LVH is mostly persistent and progressive despite anti-hypertensive drug treatment, 6 some studies have shown a remarkable reversal of LVH in ESRD patients treated by strict fluid volume control without drugs. 7, 8 The exact pathophysiology of LVH in ESRD patients is unknown, but hypertension, volume overload, anaemia, uraemia and arteriovenous shunts are implicated. 9, 10 In patients with systemic hypertension, the development of LVH is thought to be caused by the increased pressure load imposed on the left ventricle. In haemodialysis patients, volume overload also contributes to the maintenance of LVH. According to the Laplace equation, volume overload leads to a proportional increase in wall thickness in order to normalize wall stress. The increase in muscle mass associated with volume overload is considerably greater than that associated with pressure overload because of the increased diameter of the left ventricle.
We aimed to compare the left ventricular mass, measured echocardiographically, in three groups of haemodialysis patients: those rendered normotensive by applying strict fluid volume control alone; those rendered normotensive by treatment with anti-hypertensive drugs; and those who were hypertensive despite the use of hypotensive drugs.
Patients and methods

PATIENTS
Three groups of haemodialysis patients were identified from two dialysis centres. At the Firat University Medical School (Elazig, Turkey) dialysis centre we use a regimen involving strict fluid volume control. Antihypertensive drugs are discontinued, and the need for salt restriction is emphasized, by explaining to patients and their families the implications of a salt-restricted diet and the need to avoid ready-made food. Repeated instructions are often required to bring about a change in dietary behaviour. Using this approach, the estimated salt intake is around 4 -5 g/day. Patients are allowed to drink as much as their thirst indicates, as long as salt is restricted. The dialysis patients from our centre who had normal blood pressure without drug treatment comprised group A.
Group B and group C were identified from patients dialysed at the Elazig Social Security Hospital haemodialysis centre, where strict fluid volume control was not used. The patients recruited to group B had had normal blood pressure levels (pre-dialysis blood pressure ≤ 140/90 mmHg) with antihypertensive treatment for at least 6 months before the study. Group C comprised patients who remained hypertensive even with treatment.
Patients who had valvular heart disease, cardiac arrhythmia or conduction defects, regional wall motion abnormalities or technically uninterpretable two-dimensional echocardiograms were excluded from the study. As far as we are aware, there was no bias in the different patient groups. Informed consent was obtained from all patients, and the Firat University Hospital Ethics Committee approved the study design.
HAEMODIALYSIS
All patients received haemodialysis for 4 h three times weekly, using bicarbonate dialysis fluid containing 138 mmol/l sodium and 3 mEq/l calcium in a polysulphone dialyser (Fresenius Company, Bad Hamburg, Germany) with a surface area of 1.3 -1.6 m 2 . The blood flow was 250 -300 ml/min, and the dialysate flow was 500 ml/min. Ultrafiltration was controlled volumetrically.
Before dialysis, blood pressure was measured using a sphygmomanometer, and the mean of at least three consecutive predialysis values was calculated for each patient. Blood samples for laboratory analysis were also taken before dialysis. Patients were weighed before and after dialysis. The interdialytic weight gain was calculated using the mean weight values before and after the last month of dialysis.
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ECHOCARDIOGRAPHY
All patients underwent echocardiography on an interdialytic day. Echocardiographic examination was performed using an ATL-Ultramark 9 ultrasonoscope (Bothell, WA, USA) with 2.5 MHz transducer, in accordance with the American Society of Echocardiography recommendations. 11 All measurements were made by an experienced echocardiographer who was blinded to the patient group. Each value measured was averaged over three cardiac cycles. The left atrial size and the left ventricular endsystolic and end-diastolic diameters were indexed by body surface area. In addition, the left ventricular mass index (LVMI) was calculated using the following equation:
where IVST is the interventricular septum thickness, LVDd is the left ventricular enddiastolic dimension and PWT is the posterior wall thickness. Body surface area (BSA) was measured by the DuBois formula:
Left ventricular systolic function was assessed by the left ventricular ejection fraction. Peak-flow velocities of the early and late diastolic fillings and their ratios were used in the assessment of left ventricular diastolic performance.
STATISTICAL ANALYSES
Differences in mean values were tested using the Kruskal-Wallis one-way analysis of variance test, and the significance of the differences between the groups was calculated using the Mann-Whitney U-test. Differences in proportions were tested using the χ 2 -test. A P-value < 0.05 was considered to be significant. All data are given as the mean ± SD.
Results
Baseline demographic, clinical and laboratory data for all 106 patients in the study are given in Table 1 . None of the patients had residual renal function.
All of the patients in group B and group C were taking anti-hypertensive drugs. Nine of the 23 patients (39%) in group B required three types of anti-hypertensive drug (calcium antagonists, angiotensinconverting enzyme [ACE] inhibitors and vasodilators) to control their hypertension, while the remaining 14 patients (61%) received two anti-hypertensive medications (calcium antagonists and ACE inhibitors).
Baseline blood pressure and echocardiographic data for the three groups of patients are given in Table 2 .
The cardiac dimensions were larger in group C compared with group B, but the differences failed to reach statistical significance.
Discussion
The results of this study confirm that satisfactory blood pressure can be achieved by pre-load reduction via strict control of salt intake alone. They not only support the hypothesis that a decrease in volume may be more important than pressure reduction in obtaining this goal, but also suggest that correction of relatively small degrees of volume excess may be essential for obtaining regression of left ventricular hypertrophy.
The echocardiographically measured dimensions of the heart were significantly larger in group B patients, who were normotensive with drugs, than in group A patients. Although the blood pressure levels Strict fluid volume control and LVH in haemodialysis patients in group B were slightly higher than those in group A, these echocardiographic differences suggest that the failure to reduce the LVH in these patients was related to a persistent, discrete degree of volume expansion. In addition, the LVMI in this group (B) was similar to that of group C, despite much higher blood pressures in the latter group. The volume overload was more evident in group C (hypertensive despite drug treatment) than in group B. Whether or not this was the reason that drugs failed to control blood pressure in group C cannot be determined because the treatment schedules were not identical. Interdialytic weight gain was significantly higher in group B and group C than in group A, presumably because of better compliance with salt restriction in group A.
In contrast to essential hypertension, 12 there is little information on the reversal of LVH in dialysis patients. A limited number of publications report regression of LVH in Strict fluid volume control and LVH in haemodialysis patients haemodialysis patients treated with antihypertensive drugs. Cannella et al. 13 observed a decrease in blood pressure and a reduction in LVH on echocardiography after 24 months of treatment with an ACE inhibitor, a β-blocker and a calcium-channel blocker.
There was a concomitant decrease in the left ventricular diastolic diameter. This may be due to a specific action of the anti-hypertensive drugs or may be secondary to the decrease in intravascular volume and blood pressure; the authors supported the latter possibility.
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London et al. 14 compared the effect of two different anti-hypertensive drugs: the ACE inhibitor perindopril and the calciumchannel blocker nitrendipine. Both drugs achieved a similar decrease in blood pressure, but a significant reduction in left ventricular mass was only found in the perindopril group. There was also a marked decrease in the left ventricular diastolic diameter in the perindopril group but not in the nitrendipine group. The authors attributed these results to a reduction in preload caused by dilatation of the venous system in the perindopril group.
Two more recent studies have reported the regression of LVH in haemodialysis patients receiving nocturnal or short daily haemodialysis. 15, 16 Chan et al. 15 compared the effect of two modes of renal replacement therapyconventional and nocturnal haemodialysison blood pressure control and left ventricular mass. After the conversion from conventional to nocturnal haemodialysis, significant reductions in blood pressure, left ventricular mass and the number of prescribed hypotensive drugs were seen. A decrease in left ventricular mass is accompanied by a reduction in the left ventricular diastolic diameter. As these treatment modalities greatly facilitate volume control, it is tempting to ascribe these results to a decrease in blood volume and pre-load.
The importance of reversing increased pre-load was illustrated by the report of Ozkahya et al., 7 who showed that reversal of hypervolaemia through reduced dietary salt intake and ultrafiltration caused a reduction in LVH in dialysis patients, even without the use of anti-hypertensive agents. All of the above studies support the importance of a reduction in the left ventricular volume for the regression of LVH.
The results of group A in the present study show that control of LVH with volume reduction was also associated with a significant improvement in the diastolic function, as evidenced by an increase in the ratio of the early and late diastolic peak flow velocities of the left ventricle. We suggest that this is due to a reduction in the left ventricular mass, which increases left ventricular muscle compliance.
There was no difference in the haemoglobin levels in our groups, but anaemia is one of the most important causes of LVH. 17, 18 In chronic anaemia there is a reduction in after-load due to arterial dilatation caused by decreased vascular resistance, similar to that produced by antihypertensive drugs. This vasodilatation facilitates pressure transmission from the arterial system to the venous circulation, increasing pre-load and cardiac filling. Even though anaemic patients have a normal blood pressure due to decreased arterial resistance, this volume overload leads to progressive cardiac enlargement and LVH. 19 By way of analogy, we suggest that lowering volume-induced hypertension with hypotensive drugs mirrors the state of LVH in patients with anaemia.
Anti-hypertensive drugs lower the blood pressure via arterial vasodilatation, as in anaemia, but cannot, at least in dialysis patients, correct the hypervolaemia. Thus the increased pre-load will persist and LVH progresses. In our study, patients in group B had a significantly increased left atrial diameter, suggesting increased pre-load. This may explain why their LVH persisted, despite relatively good blood pressure reduction with anti-hypertensive drugs. It was surprising that the LVH seen in group C was hardly more than that in group B, despite much higher blood pressure levels. This finding may be due to variations in the duration of blood pressure control in the different groups. Strict fluid volume control and LVH in haemodialysis patients Our results are interesting, but the limitations of the study must be borne in mind. The cross-sectional design precludes the assessment of time-dependent changes; the number of patients studied was relatively small, which does not permit firm conclusions about the differences between the groups. Despite the encouraging results obtained with strict fluid volume control, a study comparing the effects on LVH of volume control and hypotensive drugs would be unethical. This is because some patients would not be applying strict volume control and therefore may not be getting the best treatment for the trial's duration. For this reason, we have not planned a prospective study in our centre.
In summary, we have shown that strict fluid volume control not only decreases blood pressure but also reduces dilated cardiac compartments and corrects LVH more effectively than lowering the blood pressure without correcting the volume overload. This is consistent with most of the data available in the literature. 
